VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GOVXGeoVax Labs, Inc.
$1.34$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksGOVXCash Flow

GeoVax Labs, Inc. (GOVX) Cash Flow Statement

29Y historyFree accessUpdated daily

Persistent negative free cash flow, often exceeding $5 million per quarter, highlights a structural inability to self-fund operations, leaving the company with a thin current ratio of 1.06 as of 2026Q1.

GOVX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations-19.05M-21.47M-24.68M-25.17M-19.03M-11.2M-2.75M-1.4M-1.54M-1.69M-1.95M-2.71M-2.25M-1.69M-2.44M-303.62K-2.01M-1.43M-2.37M-3.27M-1.33M-1.43M-1.23M288.31K-4.21M-6.33M-4.46M-5.35M-2.45M-1.17M
Operating CF Margin %--862.7%-623.97%--23342.5%-2904.38%-150.83%-118.93%-160.23%-157.03%-234.78%-631.95%-254.84%-70.1%-91.88%-6.2%-38.71%-38.85%-81.37%-1377.93%-155.7%----160.79%-735.88%-195.59%-99.69%-89.63%-1240.33%
Operating CF Growth %-13.41%12.97%1.98%-32.28%-69.97%-307.06%-96.68%9.37%8.61%13.24%28.06%-20.23%-32.78%30.59%-704.04%84.87%-40.84%39.81%27.49%-145.93%6.91%-15.53%-528.24%106.84%33.42%-41.95%16.7%-118.69%-109.99%-
Net Income-21.37M-21.46M-24.99M-25.97M-14.02M-18.57M-2.96M-2.37M-2.56M-2.17M-3.27M-2.69M-2.73M-2.28M-2.14M-2.35M-2.75M-3.28M-3.73M-4.24M-584.17K-1.41M-2.21M-3.08M-13.25M-8.82M-9.31M-6.13M-3.99M-1.39M
Depreciation & Amortization63.91K68.76K95.37K74.17K56.28K38.52K19.66K8.35K19.8K28.03K28.78K28.93K69.04K78.86K93.64K109.02K119.77K89.78K61.01K54.46K49.09K0269.59K519.17K1.63M827.35K1.1M318.4K93.67K33.46K
Stock-Based Compensation1.04M1.12M528.64K1.07M902.07K369.99K64.46K327.5K469.72K57.22K967.67K67.91K479.1K402.1K310.08K773K750.53K1.3M2.02M00000000000
Deferred Taxes0000-3.65M00000-967.67K-67.91K-479.1K-402.1K-310.08K2.35M-750.53K-1.3M-2.02M00000000000
Other Non-Cash Items00003.65M37.77K124.19K018.26K-296.48K967.67K67.91K479.1K402.1K310.08K-1.92M750.53K1.3M2.02M1.52M58.56K-145.39K809.3K346.56K7.1M2.84M4.3M902.05K13.13K0
Working Capital Changes1.22M-1.19M-307.23K-356K-5.97M6.93M-806636.28K527.54K396.45K329.13K-112.82K-64.69K109.39K-709.83K730.79K-130.15K470.66K-719.76K-596.9K-851.43K127.48K-105.74K2.5M313.67K-1.17M-557.8K-440.05K1.43M196.14K
Change in Receivables1.5M659.41K-659.41K049.01K133.66K-114.06K53.21K-62.06K-31.68K91.9K-40.64K61.57K125.34K-82.73K000000000000000
Change in Inventory0000-49.01K-133.66K114.06K00000000000000000-390.06K470.22K-361.5K-1.42M1.89M22.81K
Change in Payables-690.63K0-412.55K-1.23M-2.69M6.81T137.96B639.28K553.12M441.44K-60.03M-60.03M-125.33K-14.69K-614.5K419.93M39.03M224.94M-252.12K00000000000
Cash from Investing-10.72K-27.61K-20.65K-48.95K-134.26K-47.72K-156.79K-7.61K0-4.35K-15.85M-15.85K-35.5K-86.6K0-11.9K874-270.25K-99.83K0-69.47K007.67K-661.28K-6.03M-15.68K-1.37M-201.97K-81.21K
Capital Expenditures-10.72K-27.61K-20.65K-48.95K-134.26K-47.72K-156.79K-7.61K0-4.35K-15.85M-15.85K-35.5K-86.6K0-11.9K-4.71K-270.25K-99.83K0-69.47K000-661.28K-2.19K-25.68K-1.07M-201.97K-81.21K
CapEx % of Revenue1.26%1.11%0.52%-164.68%12.38%8.6%0.65%-0.4%1912.13%3.7%4.02%3.58%-0.24%0.09%7.37%3.43%-8.14%---25.24%0.26%1.13%19.91%7.4%86.44%
Acquisitions0000000000000000000000000-6.03M0000
Investments------------------------------
Other Investing00000000000000005.58K0000007.67K0010K-300K00
Cash from Financing12.89M19.08M23.75M4.06M35.35M12.78M12.51M1.43M1.49M1.55M1.34M2.68M873.4K3.26M2.31M404.41K-430.4K3.02M2.67M3.17M2.21M1.5M1.24M-393.11K2.92M15.01M4.45M3.15M5.65M1.77M
Debt Issued (Net)00-15K00-27.86K1.05M-10.26K300K000000000000476.4K1.14M-1.64K-89.67K-373.91K286K162.61K-706.39K1.17M
Equity Issued (Net)12.89M19.08M21.4M4.06M27.73M9.41M11.46M1.44M1.19M01.34M2.68M873.4K3.26M2.31M404.41K-430.4K3.02M2.67M3.17M2.21M550K323K104.9K505.86K15.38M2.39M06.32M604.42K
Dividends Paid000000000000000000000000000000
Share Repurchases00000-1K0000000000000000000000-341.37K-1.19M
Other Financing002.37M07.63M3.4M2.5K001.55M00000000000470.59K-224.41K-496.38K2.5M01.78M2.99M31.16K0
Net Change in Cash-6.17M-2.42M-945.65K-21.16M16.19M1.54M9.6M23.64K-53.03K-141.3K-606.32K-41.3K-1.41M1.48M-132.06K88.89K-2.44M1.32M200.82K-97.79K815.44K70.55K7.5K-97.14K-1.96M2.65M-24.61K-3.57M3M528K
Free Cash Flow-19.05M-21.5M-24.7M-25.22M-19.16M-11.24M-2.91M-1.41M-1.54M-1.69M-17.8M-2.72M-2.29M-1.78M-2.44M-315.52K-2.01M-1.7M-2.47M-3.27M-1.4M-1.43M-1.23M288.31K-4.87M-6.33M-4.48M-6.42M-2.65M-1.25M
FCF Margin %-2234.71%-863.81%-624.5%--23507.18%-2916.76%-159.42%-119.58%-160.23%-157.43%-2146.91%-635.65%-258.86%-73.68%-91.88%-6.44%-38.8%-46.22%-84.8%-1377.93%-163.84%----186.03%-736.13%-196.71%-119.6%-97.03%-1326.78%
FCF Growth %23.75%12.94%2.09%-31.61%-70.44%-286.75%-106.77%8.87%8.85%90.49%-554%-19.05%-28.32%27.04%-673.73%84.32%-18.67%31.3%24.44%-133.7%2.04%-15.53%-528.24%105.91%22.99%-41.18%30.17%-142.36%-112.51%-
FCF per Share-9.48-22.43-119.03-248.27-188.64-110.68-28.62-13.84-15.19-16.66-175.17-26.78-22.50-17.53-24.03-3.11-19.80-16.69-24.29-32.14-13.75-14.04-12.152.84-47.98-62.30-44.13-63.19-26.07-12.27
FCF Conversion (FCF/Net Income)0.89x1.00x0.99x0.97x1.36x0.60x0.93x0.59x0.60x0.78x0.59x1.01x0.82x0.74x1.14x0.13x0.73x0.43x0.64x0.77x2.27x1.01x0.56x-0.09x0.32x0.72x0.48x0.87x0.61x-0.03x
Interest Paid000000000000000000000000000000
Taxes Paid000000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Insufficient liquidity for operations

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Disconnect Masks Cash Burn

According to the provided quarterly data, the OCF/NI ratio has fluctuated significantly, reaching as high as 1.60 in 2024Q3, which suggests that net income figures frequently fail to capture the full extent of the company's underlying cash consumption during periods of intense clinical development activity.

The divergence between net income and operating cash flow indicates that non-cash items and working capital swings are obscuring the true velocity of capital depletion. Investors should monitor this relationship closely, as the inability to align accounting losses with cash outflows suggests a lack of operational predictability.

Persistent Negative Free Cash Flow

As reported in financial statements, GeoVax consistently records negative free cash flow, with quarterly outflows often exceeding $5 million, highlighting a structural inability to self-fund operations through its current grant-based revenue model without relying on external capital markets for survival.

The persistent negative FCF trajectory confirms that the company remains in a capital-intensive phase where every dollar of research progress is funded by equity dilution. This trend warrants further investigation into whether the company can reach a value-inflection point before its current cash runway is fully exhausted.

Volatile Working Capital Obscures Liquidity

Based on GeoVax's reported figures, working capital changes have been highly erratic, swinging from a $3.0 million inflow in 2024Q2 to a $3.6 million outflow in 2024Q3, which reflects the lumpy nature of grant-based receivables and the timing of project-related vendor payments.

These sharp fluctuations in working capital suggest that the company's liquidity is highly sensitive to the timing of government funding disbursements. Such volatility makes it difficult to forecast short-term cash needs, potentially forcing management into suboptimal financing decisions during periods of delayed grant receipts.

SBC and Liabilities Mask Reality

Analysis of recent filings reveals that stock-based compensation remains a recurring non-cash expense, while the absence of significant capital expenditures suggests that the company's primary cash drain is driven by operational R&D burn rather than investment in long-term tangible infrastructure or manufacturing capacity.

The reliance on stock-based compensation to preserve cash may indicate management's attempt to mitigate immediate liquidity pressure, though this comes at the cost of ongoing shareholder dilution. The lack of meaningful CAPEX implies that the company is not currently scaling its own production capabilities, keeping it tethered to a high-burn, research-only operational profile.

GOVX — Frequently Asked Questions

Quick answers to the most common questions about buying GOVX stock.

How much cash does GeoVax Labs, Inc. (GOVX) generate from operations?

GeoVax Labs, Inc. (GOVX) generated $-21.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is GeoVax Labs, Inc.'s free cash flow?

GeoVax Labs, Inc. (GOVX) reported negative free cash flow of $21.5M in 2025, indicating capital requirements exceeded cash from operations.

What is GeoVax Labs, Inc.'s capital expenditure (CapEx)?

GeoVax Labs, Inc. (GOVX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.